Lilly expands Zepbound self-pay availability to major retail pharmacies, no longer limiting discounted pricing to LillyDirect platform.
The GLP-1 medication market faces mounting complexity over shortages, compounding controversies, and insurance coverage battles.
Ohio legislators propose requiring health insurers to cover menopause treatments including hormone therapy and counseling.
Global exosome therapy market projected to reach $307 billion by 2035 as regenerative medicine applications expand rapidly.
New review explores how cellular vesicles called exosomes may treat type 2 diabetes and prevent complications like neuropathy and kidney disease.
Indian pharmaceutical companies are producing GLP-1 weight-loss drugs at dramatically lower prices than Western brands.
Experts say evidence for NAD+ supplements extending human lifespan remains inconclusive despite their popularity among longevity seekers.
Patent expiration in India may not guarantee access to affordable semaglutide due to manufacturing and infrastructure challenges.
Many patients who stop GLP-1 medications restart treatment or switch to alternatives, highlighting the chronic nature of obesity care.
Peptide supplements promise biohacking benefits, but scientific evidence remains thin despite aggressive marketing claims.